{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T06:32:01Z","timestamp":1775111521923,"version":"3.50.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>COVID-19 treatment guidelines recommend baricitinib or tocilizumab for the management of hospitalized patients with COVID-19. We compared the effectiveness of baricitinib vs. tocilizumab on mortality and clinical outcomes among hospitalized patients with COVID-19.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Multicenter, retrospective, propensity-weighted cohort study using a target trial emulation approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>The National COVID Cohort Collaborative (N3C), which is the largest electronic health records data on COVID-19 in the United States. The setting included 75 hospitals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS:<\/jats:title>\n            <jats:p>Adults who were hospitalized for COVID-19.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INTERVENTIONS:<\/jats:title>\n            <jats:p>Newly initiated on baricitinib or tocilizumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n            <jats:p>Our primary outcome was 28-day mortality. We used propensity scores with inverse probability of treatment weights (IPTWs) to control bias and confounding while comparing treatments. Among 10,661 individuals included in the study, 6,229 (58.4%) received baricitinib and 4,432 (41.6%) tocilizumab. Overall, the mean age of the cohort was 60.0\u2009\u00b1\u200915.1 years, 6429 (60.3%) were male, and 19.2% received invasive mechanical ventilation. After IPTW adjustment, baricitinib use was associated with lower 28-day mortality (odds ratio [OR], 0.91; 95% CI, 0.85\u20130.98) and hospital (OR, 0.88; 95% CI, 0.82\u20130.94) mortality compared with tocilizumab. Baricitinib was also associated with shorter hospital length of stay (incident rate ratio, 0.92; 95% CI, 0.90\u20130.94) and lower rates of hospital-acquired infections (OR, 0.86; 95% CI, 0.75\u20130.99), although no difference in ICU length of stay was noted between the two groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>In this large, diverse cohort of U.S. hospitalized adults with COVID-19, baricitinib was associated with significantly lower 28-day mortality, hospital mortality, shorter hospital length of stay, and less hospital-acquired infections compared with tocilizumab.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ccm.0000000000006444","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T14:00:20Z","timestamp":1728050420000},"page":"e29-e41","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Comparative Effectiveness of Baricitinib Versus Tocilizumab in Hospitalized Patients With COVID-19: A Retrospective Cohort Study of the National Covid Collaborative"],"prefix":"10.1097","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-4703","authenticated-orcid":false,"given":"Asad E.","family":"Patanwala","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, NSW, Australia."},{"name":"Department of Pharmacy, Royal Prince Alfred Hospital, Camperdown, NSW, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuya","family":"Xiao","sequence":"additional","affiliation":[{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD."},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Hills","sequence":"additional","affiliation":[{"name":"Medical Research Institute of New Zealand, Wellington, New Zealand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisa M.","family":"Higgins","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin J.","family":"McArthur","sequence":"additional","affiliation":[{"name":"Auckland City Hospital, Auckland, New Zealand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD."},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD."},{"name":"Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemalkumar B.","family":"Mehta","sequence":"additional","affiliation":[{"name":"Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD."},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of National Covid Cohort Collaborative (N3C) Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"R1-20250131"},{"key":"R2-20250131"},{"key":"R3-20250131","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and Future Prospects.","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"R4-20250131","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised, placebo-controlled trial.","volume":"10","author":"Ely","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R5-20250131","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial.","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"R6-20250131","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial and updated meta-analysis.","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"R7-20250131","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19.","volume":"384","author":"Investigators","year":"2021","journal-title":"N Engl J Med"},{"key":"R8-20250131","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19.","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"R9-20250131","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.cmi.2022.10.015","article-title":"Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: An open label, randomized controlled trial.","volume":"29","author":"Karampitsakos","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"R10-20250131","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/phar.2867","article-title":"Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study.","volume":"44","author":"Conroy","year":"2023","journal-title":"Pharmacotherapy"},{"key":"R11-20250131","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/CCM.0000000000005756","article-title":"Outcomes and adverse effects of baricitinib versus tocilizumab in the management of severe COVID-19.","volume":"51","author":"Peterson","year":"2023","journal-title":"Crit Care Med"},{"key":"R12-20250131","doi-asserted-by":"crossref","first-page":"ofad426","DOI":"10.1093\/ofid\/ofad426","article-title":"Comparison of tocilizumab vs baricitinib in clinical outcomes among hospitalized patients with COVID-19: Experience from a public hospital system in New York City.","volume":"10","author":"Sunny","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R13-20250131","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"R14-20250131"},{"key":"R15-20250131"},{"key":"R16-20250131","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"R17-20250131","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2665-9913(21)00325-8","article-title":"Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: A retrospective cohort study using data from the National COVID Cohort Collaborative.","volume":"4","author":"Andersen","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R18-20250131"},{"key":"R19-20250131"},{"key":"R20-20250131","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"R21-20250131","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: Choosing a threshold for considering residual imbalance.","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"R22-20250131","doi-asserted-by":"crossref","first-page":"ofad205","DOI":"10.1093\/ofid\/ofad205","article-title":"Baricitinib treatment of coronavirus disease 2019 is associated with a reduction in secondary infections.","volume":"10","author":"Sweeney","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R23-20250131","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/08971900221100205","article-title":"Bioavailability of orally administered drugs in critically ill patients.","volume":"36","author":"Forsberg","year":"2022","journal-title":"J Pharm Pract"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000006444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T17:04:43Z","timestamp":1738343083000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000006444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000006444","relation":{},"ISSN":["0090-3493","1530-0293"],"issn-type":[{"value":"0090-3493","type":"print"},{"value":"1530-0293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]}}}